Abbott India Ltd Share Price (ABBOTINDIA)

Abbott India Ltd is a leading multinational pharmaceutical company in India, with its headquarters in Mumbai. It has manufacturing facilities in Goa and independent contract/third party manufacturers based across the country. The company provides products and solutions across therapeutic areas such as Womens Health, Gastroenterology, Central Nervous System, Metabolics, MultiSpecialty, Vaccines and Consumer Health. In 2002, they sold their Jejuri Undertakings with assets and liabilities as a going concern. In 2003, they amalgamated Knoll Pharmaceuticals Ltd with the company. In 2004, they started capsule production with a capacity of 27 million nos. and in 2005, they further increased the capacity to 56 million nos. and started a new project of producing nutritional products with installed capacity of 600 tonnes. In 2006, the production capacity of Tablets was also increased by 236 million nos to 686 million. In 2008, they launched Digene Total buffered pantoprazole tablet, Bruge, and Thyronorm 150 Digene along with Sugar Free Tablet and Gel. In 2018, Abbott India Ltd formed a new Business Unit GI Advance which followed a Build Operate Transfer model. During the year 2020-21, the company made an innovation in Brufen Coating formula leading to 50% increase in coating installed capacity. It further executed 8 new studies and published 8 articles in major indexed journals. Abbott India also launched 10 new products in various therapy segments leading to their recognition as The Most Innovative MNC of the Year 2019 at the 12th Pharma Leaders Award. The Drug Price Control Order 2013 brought several products of Abbott India under price control, leading to an adverse impact on sales and profits. They also received approvals to conduct phase 3 studies in adults/eldery and pediatric for their Influvac Quadrivalent Vaccine QIV Program. Abbott India has been making continuous efforts for portfolio expansion launching unique products and leveraging technology for better healthcare outcomes.

Revenue: ₹1,604.59Cr as on March 2025 (Q4 FY25)
Net Profit: ₹367.04Cr as on March 2025 (Q4 FY25)
Listing date: 03 Nov, 1994
Chairperson Name: Munir Shaikh